Avalyn Pharma Inc. (AVLN) stock
AVLNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026
$27.92−1.84 (-6.18%)
Close on Nov 17, 2026Market cap $1.24BP/E –Yield –
Avalyn Pharma r&d expenses
Research and development expenses are spending on new products and technology.
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $24.73M | – |
| Q1 FY2026 | Mar 31, 2026 | $22.89M | – |
| Q2 FY2025 | Jun 30, 2025 | $17.88M | – |
| Q1 FY2025 | Mar 31, 2025 | $15.32M | – |
See a number that looks wrong?